Nephrology Hypertension

Medical Management of the Dialysis Patient: Blood Pressure and Fluid Volume Management

Does this dialysis patient have hypertension?

The National Kidney Foundation’s Kidney Disease Outcome Quality Improvement program (KDOQI) published a guideline calling for a pre-dialysis systolic blood pressure (SBP) <140 mmHg. The evidence supporting this guideline was graded as weak since it was largely extrapolated from the general population in which a continuous reduction in cardiovascular disease (CVD) risk accompanies each mm Hg drop in SBP. Despite the continuing uncertainty surrounding the applicability of data derived from the general population to dialysis patients, the current definition of hypertension for dialysis patients is based on the KDOQI target.

Is he/she fluid overloaded?

The current definitions of "dry weight" and volume overload are vague. A patient’s estimated dry weight (EDW) is based on clinical assessment. It is usually determined by successively decreasing the post-dialysis weight until clinical symptoms or intradialytic hypotension occur. A variety of Imaging techniques have been proposed to aid in establishing the EDW (See imaging section below).

What tests to perform?

Blood pressure measurements

Routine dialysis unit systolic blood pressure measurements have significant limitations. The vast majority of dialysis clinics do not adhere to the American Heart Association (AHA) guidelines. Moreover, large inter and intra-patient variability has been reported, using routine dialysis unit blood pressure measurements. "Out of dialysis unit" blood pressure measures; eg, home blood pressure monitoring (HBPM) and ambulatory blood monitoring (ABPM) may be more strongly associated to clinical outcomes. However, adherence to HBPM and ABPM schedules may be poor. Furthermore, whether ABPM are the most reflective measures of a patient’s true blood pressure remains controversial. Finally, current clinical guidelines for the diagnosis and treatment of hypertension in hemodialysis patients are based on routine pre-dialysis systolic blood pressure.

Laboratory testing

Several biomarkers have been advocated as potential indicators of volume overload (atrial natriuretic peptide [ANP], brain natriuretic peptide [BNP] and cylic guanosine monophosphate [cGMP]). However, all are fraught with excessive variability and poor correlation with volume status.


Since EDW is difficult to assess by physical exam, other methods have been used to guide ultrafiltration; eg, extracellular fluid volume (ECFV) measurement by bioelectrical impedance, ultrasonic measurement of the inferior vena cava diameter and collapsibility upon inspiration, and continuous intra-dialytic blood volume monitoring. These measures suffer from operator dependence, low accuracy and/or precision, and impracticality. However none is sufficiently reliable to justify routine use in clinical practice.

How should patients with hypertension and fluid overload be managed?

Management of fluid overload

Dietary sodium restriction

The 2005 KDOQI Guidelines K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients recommend reducing dietary sodium and ECFV as first steps in treating hypertensive dialysis patients. In the 2006 Update for Hemodialysis Adequacy, KDOQI states that “daily dietary sodium intake should not exceed 5g of sodium chloride (2.0g or 85 mmol of sodium).


Avoidance of large interdialytic weight gains and control o ECFV facilitate blood pressure control. Ultrafiltration is an effective way to achieve EDW and lower blood pressure. Aggressive ultrafiltration may lead to regression in left ventricular mass, decreased left atrial and left ventricular systolic and diastolic pressures. Kayikiouglu et al. reported that the combination of dietary sodium restriction and ultrafiltration decreased the use antihypertensive agents and the prevalence of left ventricular hypertrophy. Given the lack of reliability of instrumental exams aimed at assessing ECFV, ultra filtration goals and EDW remain largely based on accurate physical exam and clinical assessment. Based on KDOQI recommendation, ultrafiltration “should be optimized with a goal to render the patient euvolemic and normotensive.”

Dialysate sodium concentration. Changes in dialysate sodium concentration may alter blood pressure. A variable dialysate sodium concentration may lower antihypertensive medications requirement. A randomized crossover study demonstrated that a programmed decreased in sodium dialysate concentration from 155 to 135 mEq/L vs. a stable sodium dialysate concentration of 140 mEq/L lowered post-dialysis BP from 133/69 to 126/66 (p<0.05) and the use of antihypertensive medications. A fixed lower dialysate sodium concentration, in combination with dietary salt restriction, may also lower blood pressure. Sodium neutral profiling may reduce intradialytic hypotension without increasing interdialytic weight gain. However, increasing positive sodium balance by “sodium profiling” or using a high dialysate sodium concentration should be avoided.

Management of hypertension

Pharmacological agents commonly used in the treatment of hypertension in dialysis patients include:


To promote loss of sodium and water from dialysis patients, large doses of potent loop diuretics, such as furosemide, bumetanide, or torsemide can be administered. In the International Dialysis Outcomes and Practice Patterns Study (DOPPS), diuretic prescription was associated with lower interdialytic weight gain.

However, diuretic therapy is effective only when the daily urine output is at least 100 ml. Furthermore, the effectiveness of diuretic therapy may not last long over time, likely due to the loss of residual kidney function. Finally, ototoxicity should always be considered as a potential side effect of high-dose loop diuretics, especially furosemide.

Angiotensin Converting Enzyme Inhibitors (ACEi) and Angiotensin Receptor Blockers (ARBs)

Zannad et al. demonstrated that lower blood pressure in HD patients randomized to fosinopril was associated with a trend toward decreasing CVD events (RR: 0.79, 0.59-1.1, p=0.99). In a trial comparing candesartan vs. placebo, CVD events and mortality were higher in controls (45.9% vs. 16.3% and 18.9% vs. 0.0%, respectively (p<0.001)). Blood pressure changes were similar in the two groups, thus, the beneficial effects of ARBs may be independent of changes in BP. This is consistent with a prior report that the beneficial effects of ACEi in HD patients may also be independent of changes in blood pressure.

Suzuki et al. randomized 360 HD to either an ARB (valsartan, candesartan, or losartan) or no ARB (control). Patients were followed for 1-5 years. SBP and DBP, respectively, did not differ significantly between the two groups at 12, 24 and 36 months. For the primary endpoint, (fatal and nonfatal CVD events), event free survival was greater in the ARB vs. the control goup (p=0.001). In a Cox regression analysis, adjusted for age, sex, diabetes, SBP, and center, ARB administration was associated with a reduction in fatal and nonfatal CVD events (RR -0.51, 0.33-0.79; p=0.002). Event free survival was similar in both groups. ACEi and ARBs are well tolerated and effective. ACEi are associated with regression of LVH and may reduce mortality.

Calcium Channel Blockers (CCBs)

The USRDS Morbidity and Mortality Wave II Study suggested that CCB use was associated a 21% lower mortality risk. Subsequently, Tepel et al. randomized hypertensive hemodialysis patients to receive amlodipine or a placebo. Baseline SBP (median and interquartile range), were similar in the CCB (140 [128-160] mmHg) and control (141 [130-160] mm Hg) groups. SBP decreased from 140 (128-160) mmHg to 130 (120-147 mm Hg) in the CCB group. There was a trend toward decreased risk for the primary end-point, AC- mortality, in the CCB group (HR: 0.65, 0.34-1.23) but this did not reached statistical significance. Risk for the secondary end-point, a composite of AC-mortality, CVD events, stroke, and peripheral vascular disease requiring surgery, was reduced in the CCB group (HR: 0.53, 0.31-0.93; p=0.03) vs. the control group. CCBs are effective and well tolerated in HD patients even when volume expanded.

Beta Adrenergic Blocking agents (beta blockers)

Cice et al. conducted a RCT in which HD patients (n=144) with dilated cardiomyopathy, were randomized to a beta-adrenergic blocking agent (carvedilol), or placebo plus standard therapy. Carvedilol administration was associated with significant attenuation of pathologic remodeling with reduced left ventricular volumes and increased left ventricular ejection fraction.There were fewer deaths in the carvedilol treated group (29.3%) vs. the control group (67.9%) (p<0.0001). Foley et al. observed a robust association between therapy with beta blockers and survival.

What happens to patients with hypertension or fluid overload?

Whether the blood pressure target identified by current clinical guidelines actually contributes to improved survival of hemodialysis patients remains controversial . A recent meta-analysis concluded that decreasing SBP in HD patients lowered the number of CVD events, as well as all cause- and CVD-mortality. A RCT comparing intensive vs. standard hypertension control in HD patients is needed to assess the safety and efficacy of the KDOQI guidelines. The National Institutes of Health recently funded a pilot study (Blood Pressure in Dialysis [BID]) to assess the feasibility and safety of such a trial.

Pending results of such a trial, the available evidence indicates that HD patients with elevated BP may experience higher rates of cardiovascular events and mortality.

Similarly, poor volume control can exacerbate hypertension and its myriad detrimental effects on the cardiovascular system. Several studies support the association between fluid overload and all-cause and cardiovascular mortality. Fluid overload has also been associated with myocardial stunning and left ventricular hypertrophy.

How to utilize team care?

In order to optimally treat hypertension and fluid overload in dialysis patients, the nephrologist, nurse and renal dietitian will apply a multidisciplinary approach to optimize dialysis prescription and anti-hypertensive regimens and to minimize fluid intake.

Are there clinical practice guidelines to inform decision making?

  • K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients.

  • KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for 2006 Updates: Hemodialysis Adequacy, Peritoneal Dialysis Adequacy and Vascular Access.

What is the evidence?

"K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients". Am J Kidney Dis. vol. 45. 2005. pp. 16-153.

Agarwal, R, Alborzi, P, Satyan, S, Light, RP. "Dry-weight reduction in hypertensive hemodialysis patients (DRIP). a randomized, controlled trial". Hypertension. vol. 53. 2009. pp. 500-507.

Stidley, CA, Hunt, WC, Tentori, F, Schmidt, D, Rohrscheib, M, Paine, S, Bedrick, EJ, Meyer, KB, Johnson, HK, Zager, PG. "Changing relationship of blood pressure with mortality over time among hemodialysis patients". J Am Soc Nephrol. vol. 17. 2006. pp. 513-520.

Agarwal, R, Brim, NJ, Mahenthiran, J, Andersen, MJ, Saha, C. "Out-of-hemodialysis-unit blood pressure is a superior determinant of left ventricular hypertrophy". Hypertension. vol. 47. 2006. pp. 62-68.

Alborzi, P, Patel, N, Agarwal, R. "Home blood pressures are of greater prognostic value than hemodialysis unit recordings". Clin J Am Soc Nephrol. vol. 2. 2007. pp. 1228-1234.

Agarwal, R, Andersen, MJ. "Correlates of systolic hypertension in patients with chronic kidney disease". Hypertension. vol. 46. 2005. pp. 514-520.

Tripepi, G, Fagugli, RM, Dattolo, P, Parlongo, G, Mallamaci, F, Buoncristiani, U, Zoccali, C. "Prognostic value of 24-hour ambulatory blood pressure monitoring and of night/day ratio in nondiabetic, cardiovascular events-free hemodialysis patients". Kidney Int. vol. 68. 2005. pp. 1294-1302.

Agarwal, R, Andersen, MJ, Light, RP. "Location not quantity of blood pressure measurements predicts mortality in hemodialysis patients". Am J Nephrol. vol. 28. 2007. pp. 210-217.

Peixoto, AJ, Santos, SF, Mendes, RB, Crowley, ST, Maldonado, R, Orias, M, Mansoor, GA, White, WB. "Reproducibility of ambulatory blood pressure monitoring in hemodialysis patients". Am J Kidney Dis. vol. 36. 2000. pp. 983-990.

"K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients". Am J Kidney Dis. vol. 45. 2005. pp. S1-153.

Ishibe, S, Peixoto, AJ. "Methods of assessment of volume status and intercompartmental fluid shifts in hemodialysis patients: implications in clinical practice". Semin Dial. vol. 17. 2004. pp. 37-43.

Kotanko, P, Levin, NW, Zhu, F. "Current state of bioimpedance technologies in dialysis". Nephrol Dial Transplant. vol. 23. 2008. pp. 808-812.

Yashiro, M, Kamata, T, Yamadori, N, Tomita, M, Muso, E. "Evaluation of markers to estimate volume status in hemodialysis patients: atrial natriuretic peptide, inferior vena cava diameter, blood volume changes and filtration coefficients of microvasculature". Ther Apher Dial. vol. 11. 2007. pp. 131-137.

Reddan, DN, Szczech, LA, Hasselblad, V, Lowrie, EG, Lindsay, RM, Himmelfarb, J, Toto, RD, Stivelman, J, Winchester, JF, Zillman, LA, Califf, RM, Owen, WF. "Intradialytic blood volume monitoring in ambulatory hemodialysis patients: a randomized trial". J Am Soc Nephrol. vol. 16. 2005. pp. 2162-2169.

Agarwal, R., Mehrotra, R. "End-stage renal disease and dialysis". Nephsap. vol. 6. 2007. pp. 117-121.

"K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients". Am J Kidney Dis. vol. 45. 2005. pp. 16-153.

"Clinical practice guidelines for hemodialysis adequacy". Am J Kidney Dis. vol. 48. 2006. pp. S2-90.

Ahmad, S. "Dietary sodium restriction for hypertension in dialysis patients". Semin Dial. vol. 17. 2004. pp. 284-287.

Locatelli, F, Covic, A, Chazot, C, Leunissen, K, Luno, J, Yaqoob, M. "Hypertension and cardiovascular risk assessment in dialysis patients". Nephrol Dial Transplant. vol. 19. 2004. pp. 1058-1068.

Mailloux, LU. "The overlooked role of salt restriction in dialysis patients". Semin Dial. vol. 13. 2000. pp. 150-151.

Ozkahya, M, Ok, E, Toz, H, Asci, G, Duman, S, Basci, A, Kose, T, Dorhout Mees, EJ. "Long-term survival rates in haemodialysis patients treated with strict volume control". Nephrol Dial Transplant. vol. 21. 2006. pp. 3506-3513.

Kayikcioglu, M, Tumuklu, M, Ozkahya, M, Ozdogan, O, Asci, G, Duman, S, Toz, H, Can, LH, Basci, A, Ok, E. "The benefit of salt restriction in the treatment of end-stage renal disease by haemodialysis". Nephrol Dial Transplant. vol. 24. 2009. pp. 956-962.

Flanigan, MJ, Khairullah, QT, Lim, VS. "Dialysate sodium delivery can alter chronic blood pressure management". Am J Kidney Dis. vol. 29. 1997. pp. 383-391.

Krautzig, S, Janssen, U, Koch, KM, Granolleras, C, Shaldon, S. "Dietary salt restriction and reduction of dialysate sodium to control hypertension in maintenance haemodialysis patients". Nephrol Dial Transplant. vol. 13. 1998. pp. 552-553.

Song, JH, Park, GH, Lee, SY, Lee, SW, Lee, SW, Kim, MJ. "Effect of sodium balance and the combination of ultrafiltration profile during sodium profiling hemodialysis on the maintenance of the quality of dialysis and sodium and fluid balances". J Am Soc Nephrol. vol. 16. 2005. pp. 237-246.

Medcalf, JF, Harris, KP, Walls, J. "Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis". Kidney Int. vol. 59. 2001. pp. 1128-1133.

Wilcox, CS. "New insights into diuretic use in patients with chronic renal disease". J Am Soc Nephrol. vol. 13. 2002. pp. 798-805.

Bragg-Gresham, JL, Fissell, RB, Mason, NA, Bailie, GR, Gillespie, BW, Wizemann, V, Cruz, JM, Akiba, T, Kurokawa, K, Ramirez, S, Young, EW. "Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS)". Am J Kidney Dis. vol. 49. 2007. pp. 426-431.

Khandelwal, M, Oreopoulos, DG. "Is there a need for low sodium dialysis solution for peritoneal dialysis patients?". Adv Perit Dial. vol. 20. 2004. pp. 156-162.

Humes, HD. "Insights into ototoxicity. Analogies to nephrotoxicity". Ann N Y Acad Sci. vol. 884. 1999. pp. 15-18.

Schwartz, GH, David, DS, Riggio, RR, Stenzel, KH, Rubin, AL. "Ototoxicity induced by furosemide". N Engl J Med. vol. 282. 1970. pp. 1413-1414.

Zannad, F, Kessler, M, Lehert, P, Grunfeld, JP, Thuilliez, C, Leizorovicz, A, Lechat, P. "Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies". Kidney Int. vol. 70. 2006. pp. 1318-1324.

Takahashi, A, Takase, H, Toriyama, T, Sugiura, T, Kurita, Y, Ueda, R, Dohi, Y. "Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study". Nephrol Dial Transplant. vol. 21. 2006. pp. 2507-2512.

Efrati, S, Zaidenstein, R, Dishy, V, Beberashvili, I, Sharist, M, Averbukh, Z, Golik, A, Weissgarten, J. "ACE inhibitors and survival of hemodialysis patients". Am J Kidney Dis. vol. 40. 2002. pp. 1023-1029.

Suzuki, H, Kanno, Y, Sugahara, S, Ikeda, N, Shoda, J, Takenaka, T, Inoue, T, Araki, R. "Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial". Am J Kidney Dis. vol. 52. 2008. pp. 501-506.

Cannella, G, Paoletti, E, Delfino, R, Peloso, G, Rolla, D, Molinari, S. "Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects". Am J Kidney Dis. vol. 30. 1997. pp. 659-664.

Kestenbaum, B, Gillen, DL, Sherrard, DJ, Seliger, S, Ball, A, Stehman-Breen, C. "Calcium channel blocker use and mortality among patients with end-stage renal disease". Kidney Int. vol. 61. 2002. pp. 2157-2164.

Tepel, M, Hopfenmueller, W, Scholze, A, Maier, A, Zidek, W. "Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients". Nephrol Dial Transplant. vol. 23. 2008. pp. 3605-3612.

London, GM, Marchais, SJ, Guerin, AP, Metivier, F, Safar, ME, Fabiani, F, Froment, L. "Salt and water retention and calcium blockade in uremia". Circulation. vol. 82. 1990. pp. 105-113.

Cice, G. "Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial". 2003.

Foley, RN, Herzog, CA, Collins, AJ. "Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study". Kidney Int. vol. 62. 2002. pp. 1784-1790.

Tentori, F, Hunt, WC, Rohrscheib, M, Zhu, M, Stidley, CA, Servilla, K, Miskulin, D, Meyer, KB, Bedrick, EJ, Johnson, HK, Zager, PG. "Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization?". J Am Soc Nephrol. vol. 18. 2007. pp. 2377-2384.

Heerspink, HJL, Ninomiya, T, Zoungas, S, de Zeeuw, D, Grobbee, DE, Jardine, MJ, Gallagher, M, Roberta, MA, Cass, A, Neal, B, Perkovic, V. "Effect of Lowering Blood Pressure on Cardiovascular Events and Mortality in Patients on Dialysis: a Systematic Review and Meta-Analysis of Randomised Controlled Trials". The Lancet. vol. 373. 2009. pp. 1-7.

Banerjee, D, Ma, JZ, Collins, AJ, Herzog, CA. "Long-term survival of incident hemodialysis patients who are hospitalized for congestive heart failure, pulmonary edema, or fluid overload". Clin J Am Soc Nephrol. vol. 2. 2007. pp. 1186-1190.

Kalantar-Zadeh, K, Regidor, DL, Kovesdy, CP, Van, WD, Bunnapradist, S, Horwich, TB, Fonarow, GC. "Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis". Circulation. vol. 119. 2009. pp. 671-679.

Kimmel, PL, Varela, MP, Peterson, RA, Weihs, KL, Simmens, SJ, Alleyne, S, Amarashinge, A, Mishkin, GJ, Cruz, I, Veis, JH. "Interdialytic weight gain and survival in hemodialysis patients: effects of duration of ESRD and diabetes mellitus". Kidney Int. vol. 57. 2000. pp. 1141-1151.

Burton, JO, Jefferies, HJ, Selby, NM, McIntyre, CW. "Hemodialysis-induced cardiac injury: determinants and associated outcomes". Clin J Am Soc Nephrol. vol. 4. 2009. pp. 914-920.

Dimitrijevic, Z, Cvetkovic, T, Stojanovic, M, Paunovic, K, Djordjevic, V. "Prevalence and risk factors of myocardial remodeling in hemodialysis patients". Ren Fail. vol. 31. 2009. pp. 662-667.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs